Supplementary Tables – Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

<b>Supplementary Table 1</b>. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care <i>Patient socio-demographic and clinical characteristics at baseline in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.</i> <b>Supplementary Table 2</b>. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care <i>Clinical features of background pain and BTcP at baseline in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP</i> <b>Supplementary Table 3</b>. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care <i>Evolution of background pain and BTcP over the study period in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.</i> <b>Supplementary Table 4</b>. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care <i>Quality of life outcomes according to the EORTC QLQ-C30 in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.</i> <b>Supplementary Table 5</b>. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care <i>Global impression of improvement according to patient’s (PGI-I) and physician’s (CGI-I) perspective in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.</i>